Hostname: page-component-8448b6f56d-jr42d Total loading time: 0 Render date: 2024-04-20T05:44:30.881Z Has data issue: false hasContentIssue false
  • English
  • Français

Risk of Clostridium difficile-Associated Disease Among Patients Receiving Proton-Pump Inhibitors in a Quebec Medical Intensive Care Unit

Published online by Cambridge University Press:  02 January 2015

Mathieu Beaulieu ,
David Williamson ,
Gilbert Pichette  and
Jean Lachaine
Mathieu Beaulieu*
Affiliation:
Université de Montréal, Hôpital du Sacre-Coeur de Montreal, Quebec, Canada
David Williamson
Affiliation:
Université de Montréal, Hôpital du Sacre-Coeur de Montreal, Quebec, Canada Pharmacy, Hôpital du Sacre-Coeur de Montreal, Quebec, Canada
Gilbert Pichette
Affiliation:
Departments of Microbiology, Hôpital du Sacre-Coeur de Montreal, Quebec, Canada
Jean Lachaine
Affiliation:
Université de Montréal, Hôpital du Sacre-Coeur de Montreal, Quebec, Canada
*
Faculty of Pharmacy, Université de Montréal, PO Box 6128, succ. Centre-ville, Montreal, Quebec, CanadaH3C 3J7 (mathieu.beaulieu@umontreal.ca)
Get access Rights & Permissions [Opens in a new window]

Abstract

Our study was conducted to determine whether use of gastric acid-suppressive agents increased the risk of Clostridium difficile-associated disease (CDAD) in a medical intensive care unit of one of the first hospitals to be threatened by the current CDAD epidemic in Quebec, Canada. Our findings suggest that efforts to determine risk factors for CDAD should focus on other areas, such as older age and antibiotic use.

Type
Concise Communications
Information
Infection Control & Hospital Epidemiology , Volume 28 , Issue 11 , November 2007 , pp. 1305 - 1307
Copyright
Copyright © The Society for Healthcare Epidemiology of America 2007

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1.Centers for Disease Control and Prevention. Data and statistics about Clostridium difficile infections. Available at: http://www.cdc.gov/ncidod/dhqp/id_Cdiff_data.html. Accessed June 27, 2007.Google Scholar
2.Pindera, L. C. difficile inquest too narrow as “Quebec strain” goes international. CMAJ 2007;176:915–916.CrossRefGoogle ScholarPubMed
3.Eggertson, L, Sibbald, B. Hospitals battling outbreaks of C. difficile. CMAJ 2004;171:19–21.Google Scholar
4.Biller, P, Shank, B, Lind, L, et al. Moxifloxacin therapy as a risk factor for Clostridium difficile-associated disease during an outbreak: attempts to control a new epidemic strain. Infect Control Hosp Epidemiol 2007;28:198–201.Google Scholar
5.Yearsley, KA, Gilby, LJ, Ramadas, AV, Kubiak, EM, Fone, DL, Allison, MC. Proton pump inhibitor therapy is a risk factor for Clostridium difficile-associated diarrhoea. Aliment Pharmacol Ther 2006;24:613–619.Google Scholar
6.Kazakova, SV, Ware, K, Baughman, B, et al. A hospital outbreak of diarrhea due to an emerging epidemic strain of Clostridium difficile. Arch Intern Med 2006;166:2518–2524.Google Scholar
7.Muto, CA, Pokrywka, M, Shutt, K, et al. A large outbreak of Clostridium difficile-associated disease with an unexpected proportion of deaths and colectomies at a teaching hospital following increased fluoroquinolone use. Infect Control Hosp Epidemiol 2005;26:273–280.Google Scholar
8.Pépin, J, Saheb, N, Coulombe, MA, et al. Emergence of fluoroquinolones as the predominant risk factor for Clostridium difficile-associated diarrhea: a cohort study during an epidemic in Quebec. Clin Infect Dis 2005;41:1254–1260.CrossRefGoogle ScholarPubMed
9.Dial, S, Alrasadi, K, Manoukian, C, Huang, A, Menzies, D. Risk of Clostridium difficile diarrhea in hospital in-patients prescribed proton-pump inhibitors: cohort and case-control studies. CMAJ 2004;171:33–38.Google Scholar
10.Lozniewski, A, Rabaud, C, Dotto, E, Weber, M, Mory, F. Laboratory diagnosis of Clostridium difficile-associated diarrhea and colitis: usefulness of Premier Cytoclone A+B enzyme immunoassay for combined detection of stool toxins and toxigenic C. difficile strains. J Clin Microbiol 2001;39:1996–1998.Google Scholar
11.Cook, SF, Visscher, WA, Hobbs, CL, Williams, RL. Project IMPACT: results from a pilot validity study of a new observational database. Crit Care Med 2002;30:2765–2770.CrossRefGoogle ScholarPubMed